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The link between mutations in collagen genes and the development of Alport Syndrome has been 
clearly established and a number of animal models, including knock-out mouse lines, have been 
developed that mirror disease observed in patients. However, it is clear from both patients and 
animal models that the progression of disease can vary greatly and can be modified genetically. We 
have identified a point mutation in Col4a4 in mice where disease is modified by strain background, 
providing further evidence of the genetic modification of disease symptoms. Our results indicate that 
C57BL/6J is a protective background and postpones end stage renal failure from 7 weeks, as seen on 
a C3H background, to several months. We have identified early differences in disease progression, 
including expression of podocyte-specific genes and podocyte morphology. In C57BL/6J mice podocyte 
effacement is delayed, prolonging normal renal function. The slower disease progression has allowed us 
to begin dissecting the pathogenesis of murine Alport Syndrome in detail. We find that there is evidence 
of differential gene expression during disease on the two genetic backgrounds, and that disease 
diverges by 4 weeks of age. We also show that an inflammatory response with increasing MCP-1 and 
KIM-1 levels precedes loss of renal function.
Mutations in one of the three collagen chains present in the adult glomerular basement membrane, COL4A3, 
A4 and A51,2 can result in Alport Syndome (AS), a progressive renal disease ultimately resulting in end stage 
renal failure. Several animal models of AS have been developed and have led to a better understanding of the 
pathogenesis of this disease3–5. However, the lack of a comprehensive understanding of pathogenesis can be asso-
ciated with there are no curative treatments outside dialysis and transplantation. In patient populations3 there is 
a wide spectrum of disease severity, and from animal models there is strong evidence for genetic modification 
of the pathways leading to renal failure6,7. The increased expression of Col4a6 on the C57BL/6J background7 
ameliorates murine AS but does not account for all of the strain specific effect on disease, and other autosomal 
loci are thought to contribute to a slower disease progression on this genetic background6. However, the mech-
anisms leading to strain specific differences in disease progression are unknown. Studies of animal models have 
also highlighted several pathways that can alter the progression of AS, including modulation of the immune 
response8–10. Modulation of the renin-angiotensin system with ACE-inhibitors has also been shown to ameliorate 
disease suggesting blood pressure is an important factor in disease11.
Alport Syndrome results in an altered composition of the glomerular basement membrane and ultimately 
results in podocyte effacement and loss of glomerular function12,13. A key readout of renal function is proteinuria 
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and the presence of increased levels of urinary albumin can have a direct effect on podocytes14,15, so it is conceiv-
able that GBM dysfunction could result in proteinuria which affects podocyte function resulting in a positive 
feedback loop eventually leading to ESRF14. Supporting this notion is the observation that proteinuria precedes 
podocyte effacement in another model of GBM dysfunction, Pierson Syndrome, where alterations in podocyte 
structure and reduced expression of slit diaphragm proteins occur subsequent to proteinuria16. Furthermore, 
deletion of albumin in a model of AS ameliorates disease17. However, high levels of proteinuria do not necessarily 
result in podocyte effacement18–20. The podocyte can contribute to deterioration of renal function by the secretion 
of monocyte chemoattractant protein-1 (MCP-1), matrix metallopeptidase 12 (MMP-12) and tumour necrosis 
factor (TNF-α)14 in response to stress.
Whilst the primary defect in AS is an alteration in the composition of the GBM, there is evidence that the 
tubular response is critical to the pathogenesis of AS21–23 and may indeed precede the deterioration of glomerular 
function. Signalling between the tubule and glomerulus can influence the response of the podocytes to a collagen 
deficiency in the GBM and ameliorate disease9.
We have identified a novel mutation of Col4a4 resulting in a model of Alport Syndrome and have carried out 
a detailed analysis of disease progression and gene expression. Disease progression is greatly modified depending 
on genetic background, demonstrating C57BL/6J as a protective background6,7,24 and confirming a significant 
effect of an autosomal modifier. Examination of renal function, gene expression, and histopathology point to 
a divergence in disease progression after proteinuria and GBM alterations have occurred. A slower inflamma-
tory response, less tubular damage, and prolonged podocyte health are the key phenotypes associated with the 
improved outcome on the C57BL/6J background.
The majority of AS models developed so far have had an aggressive course with disease proceeding to ESRF 
within a matter of a few weeks. Whilst such models have contributed significantly to our understanding of AS, 
the rapid disease progression can obscure the sequence of events during pathogenesis, thus preventing a detailed 
dissection of the processes occurring in the kidney. In addition to this, the more extreme disease present on these 
backgrounds provides a compressed time frame and in comparison, to what is generally seen in patients. The rel-
atively slow progressive disease present on the C57BL/6J background provides a greater window of opportunity 
for studying mechanisms and trialling therapeutic interventions, and indeed may better model the progression 
of AS symptoms in patients.
Results
Identification of a Col4a4 mutant. As part of ongoing phenotype driven screening programme25, mutant 
mice exhibiting end stage renal disease (ESRD) between 37 and 103 days of age were identified. Kidneys from 
affected mice were small and pale and histolopathological analysis of these mice revealed extensive glomerulone-
phopathy (Fig. 1 and Fig. S1). This was associated with increased levels of serum urea and creatinine (Table S1). 
The chromosomal region containing the causative mutation was mapped to between 80 and 83 Mb on chro-
mosome 1, located in the type 4 collagen gene Col4a4 and identified through whole genome sequencing as a 
mutation in a glycine codon leading to a stop codon at amino acid 400 (Fig. 2a). Col4a4G400X/G400X mice were back-
crossed for one generation onto C3H.Pde6b+26, then inter-crossed, and subsequent breeding studies confirmed 
this as the causative mutation with a complete absence of COL4A4 protein in mutant mice (Fig. 2b).
Mutations in COL4A4 have been associated with Alport Syndrome27 and another ENU mutation in Col4a4 
has been identified which resulted in a slowly progressive disease28. However, our line appeared to have an aggres-
sive, early onset phenotype. We carried out a time course on cohorts of Col4a4G400X/G400X, Col4a4G400X/+ and wild 
type mice. Col4a4G400X/G400X mice were significantly lighter by 5 weeks of age, consumed more water and produced 
more urine from 4 weeks of age (Fig. 3a,b). Levels of albumin in the plasma of Col4a4G400X/G400X mice were sig-
nificantly lower than Col4a4G400X/+ and Col4a4+/+ mice at all of the time points analysed (Fig. 3c). Plasma levels 
of urea and creatinine increased (Fig. 3d,e), and urine levels decreased with time (Fig. 3b). Significant changes 
were observed as early as 4 weeks in homozygous mice. The protein:creatinine ratio was elevated in homozygous 
mice from 4 weeks of age, but not significantly, and the estimated glomeruar creatinine clearance decreased over 
time and was significantly lower in homozygous mice by 7 weeks of age (Fig. 3f,g). Histolopathological analysis 
revealed moderate glomerulonephropathy in the kidneys of some 4-week-old Col4a4G400X/G400X mice with almost 
all animals having a marked diffuse glomerulonephropathy affecting the whole cortex from week 7 (Fig. 1). Few 
homozygous mice reached ten weeks of age before they were culled on welfare grounds (Fig. S1).
Plasma and urine biochemistry of 20-week-old Col4a4G400X/+ and Col4a4+/+ mice were also analysed, and 
there were no significant differences in any of the parameters between the two genotypes (Fig. 3). Indeed, hete-
rozygous mice up to 2 years of age exhibited no loss of renal function (data not shown).
At 6–7 weeks of age Col4a4G400X/G400X mice underwent visual and auditory phenotyping to investigate whether 
these mice developed ocular defects and deafness as is often seen Alport patients. Optokinetic drum scores29, slit 
lamp, and opthalmoscopic observations were not significantly different from wild type controls, and auditory 
brainstem response (ABR) thresholds were also similar to wild type controls (Fig. S2), in agreement with previous 
observations in a Col4a4 mutant line30.
Genetic background modifies disease progression. Mice from the original PEDV133 pedigree were on 
a mixed background of C3H.Pde6b+26 and C57BL/6J mice (approximately 63% C3H.Pde6b+). Col4a4G400X/G400X  
PEDV133 mice have a mean survival time of 70 days, ranging from 37–103 days, suggesting an effect of the mixed 
genetic background on disease progression. To investigate the contribution of genetic background to the variation 
in disease we outcrossed Col4a4G400X/G400X one generation to each strain and then, after inter-crossing, exam-
ined homozygotes. Outcrossing to C3H.Pde6b+ reduced the survival time to a mean of 47 days whereas on the 
C57BL/6J background the mean survival time was increased to 97 days. This resulted in a significant difference in 
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the Kaplan Meyer curves depending on genetic background (Fig. 4a): C3H.Pde6b+ resulting in an earlier onset 
of disease and C57BL/6J appearing to be protective.
To further investigate disease pathogenesis on both backgrounds C3H-Col4a4G400X/G400X and B6-Col4a4G400X/
G400X mice were terminally bled at 7 weeks of age, when C3H-Col4a4G400X/G400X mice are approaching ESRD, and 
the levels of several kidney markers were compared. Both strains exhibited similar levels of hypoalbuminemia 
(Fig. 5a). Serum urea and creatinine levels in C3H-Col4a4G400X/G400X plasma were significantly higher than wild 
type mice, as expected, whereas the levels of these markers in B6-Col4a4G400X/G400X mice were similar to wild 
type levels (Fig. 5b,c). Proteinuria, urine output, and water intake showed similar increases on both backgrounds 
(Figs. S3a–c). Histopathological examination showed that C3H-Col4a4G400X/G400X animals at this time point had 
severe diffuse glomerulopathy (Fig. 1) whereas B6-Col4a4G400X/G400X exhibited minimal to moderate tubular 
changes but no significant glomerular changes (Fig. 4c).
The presence of proteinuria does not necessarily result in podocyte damage18–20. At 7 weeks of age we observed 
similar levels of hypoalbuminemia in C3H-Col4a4G400X/G400X and B6-Col4a4G400X/G400X mice, but significantly 
different levels of serum urea and creatinine, with those in B6-Col4a4G400X/G400X mice being the same as those 
in wild type mice (Fig. 5). We therefore investigated disease at an earlier time point to determine where the 
pathogenesis of disease diverged. For the majority of parameters there was a significant difference between 
wild type and mutant mice (Fig. 6a–g). For serum albumin there was only a difference between wild type and 
C3H-Col4a4G400X/G400X mice. For the other parameters, both serum and urinary, there was a significant difference 
between C3H-Col4a4G400X/G400X and B6-Col4a4G400X/G400X mice, with a milder effect of the mutation observed 
in B6-Col4a4G400X/G400X mice. Although there was not a significant difference in serum albumin levels between 
C3H-Col4a4G400X/G400X and B6-Col4a4G400X/G400X mice. Whilst there were significant differences detectable at this 
time in several plasma and urinary parameters, renal function was preserved at this age (Fig. 6h,i) suggesting that, 
despite significant differences in many parameters in mutant mice, there was a sub-clinical effect on overall renal 
function at this age. Dipstick analysis revealed significantly higher haematuria, proteinuria and leucocyte levels 
in C3H-Col4a4G400X/G400X compared to B6-Col4a4G400X/G400X mice (Fig. S4a–c). At this early time point, although 
evidence of disease was detectable in B6-Col4a4G400X/G400X mice, the overall trend was that disease pathogenesis 
had already diverged in the two strains by this time point.
Glomerular morphology was therefore assessed by SEM. At 4 weeks of age, podocyte cell bodies of 
C3H-Col4a4G400X/G400X mice appeared larger and swollen, while the foot processes were thickened, flattened, 
and irregular when compared with Col4a4G400X/+ C3H and +/+ control podocytes. By 7 weeks, the podocyte 
Figure 1. Histolopathology of mutant and wild type kidneys. Representative examples of kidneys H&E stained 
sections from (a) Col4a4+/+ and (b) Col4a4G400X/G400X G3 mice at 53 days of age at x10 magnification are shown. 
Glomerulonephropathy was seen in Col4a4G400X/G400X G3 mice and was characterised by diffuse involvement 
of glomeruli and tubules with enlargement, increased cellularity and sclerosis of glomeruli (black arrow) and 
degenerative and regenerative changes in tubules (tubular dilatation), hyaline casts (*).
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morphology showed more extreme changes in C3H-Col4a4G400X/G400X mice, with podocytes often showing com-
plete effacement. Podocyte morphology in B6-Col4a4G400X/G400X mice showed no significant changes at either time 
point (Fig. 7).
Background specific changes in podocyte gene expression. We investigated gene expression of a 
number of podocyte specific and glomerular related genes in mice from both backgrounds at 7 weeks of age 
(Fig. 8). There was no difference in Glepp1, Podxl, Npsh1 or Npsh2 (Fig. 8a–d). However, there was an increase in 
Lama5 expression on both backgrounds (Fig. 8e) whereas Agrin was upregulated in C3H-Col4a4G400X/G400X mice 
but not in B6-Col4a4G400X/G400X (Fig. 8f). Similarly, Itga3 expression increased in C3H-Col4a4G400X/G400X but not 
in B6-Col4a4G400X/G400X (Fig. 8g). Taken together these data suggest that, whilst similar processes are occurring 
in these two strains at this time point, there are also differences in the response of podocytes that may influence 
disease progression.
Reduced inflammatory markers in B6-Col4a4G400X/G400X mice. A significant difference in the inflam-
matory response between B6-Col4a4G400X/G400X and C3H-Col4a4G400X/G400X mice at 7 weeks of age was observed. 
There was reduced expression of matrix metalloproteinase 12 (MMP12) in B6-Col4a4G400X/G400X mice (Fig. 8h), 
which is expressed by podocytes in response to monocyte chemoattractant protein 1 (MCP-1, Ccl2) and has been 
demonstrated to contribute to disease31. TNF-α, another important factor in AS8, was reduced in B6-Col4a4G400X/
G400X when compared to C3H-Col4a4G400X/G400X mice (Fig. 8i).
Figure 2. An early stop mutation in Col4a4 results in the absence of protein. (a) A diagrammatic representation 
of the position of the Col4a4G400X mutation. (b) Immunofluorescence of representative wild type and mutant 
kidneys showing an absence of COL4A4 protein in mutant glomeruli. WT1 = green COL4A4 = red.
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To further investigate disease progression, we determined the expression of MCP-1 and kidney injury mol-
ecule 1 (KIM-1, Hsvcr1). MCP-1 is thought to contribute to macrophage recruitment during disease in AS32. 
KIM-1 is expressed primarily by the proximal tubular endothelial cells and its expression increases rapidly upon 
injury, thus making a potential biomarker of kidney injury (reviewed in33). For both MCP-1 and KIM-1 there was 
a greatly reduced relative level at 4 weeks and 7 weeks of age in B6-Col4a4G400X/G400X mice, with undetectable levels 
of KIM-1 at 4 weeks of age in these mice (Fig. 9).
Discussion
Through a phenotype-driven approach we have identified a mouse model of Col4a4 deficiency with an aggressive 
disease phenotype. After crossing the mutation onto the C57BL/6J and C3H genetic backgrounds there were sig-
nificant changes observed between strains, with a divergent pathogenesis from an early time point in these mice 
that may contribute to the response of the different strains downstream.
Figure 3. A time course of disease progression in wild type, heterozygous, and homozygous Col4a4G400X mice. 
Mice were housed in metabolic caging for 24-hour urine collection and water consumption then terminally  
bled and plasma levels of various parameters determined by clinical chemistry analysis on an Olympus  
AU400 analyser. (a) Plasma urea (b) Plasma creatinine (c) Plasma albumin (d) Water intake (e) Urinary output 
(f) Total urinary protein:creatinine ratio and (g) creatinine clearance. Males and females were included in the 
analysis. White = wild type, Grey = heterozygous and Black = homozygous mice. For wild-type, heterozygous, 
homozygous respectively at; 4 weeks = 4, 22, and 7; 5 weeks = 8, 12, and 11; 6 weeks = 9, 9, and 4; 7 weeks = 5, 9, 
and 6; 20 weeks = 10 wild-type and 8 heterozygotes Data shown are mean ± S.E.M. and significance determined 
within each time point group using a one-way ANOVA with Tukey’s multiple comparisons test comparing, 
one way ANOVA with Tukey’s multiple comparison test *P < 0.05, **P < 0.01, ***P < 0.001 or a T-test for 
protein:creatinine ratio and GFR.
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To investigate podocyte responses to the abnormal GBM we investigated the expression of relevant genes 
in homozygous mutant mice and controls. It should be noted that the mice used were at an early back cross 3 
generations. Whilst there are similarities between the two strains in some aspects of disease, our studies have 
identified significant differences reflecting the divergent pathways in disease pathogenesis. The increased expres-
sion of Lama5 has been observed before in models of AS34, and was observed on both backgrounds. This has 
been shown to be associated with an increased permeability of the GBM and hence is thought to contribute 
to disease pathogenesis35. Itga3 showed increased expression in C3H but not in B6 mice. Integrin α3β1 is an 
important receptor for laminin 52136 and is expressed primarily on podocytes. It is important in podocyte foot 
Figure 4. Genetic background has a significant effect on disease progression in Col4a4G400X/G400X mice. 
(a) A Kaplan-Meyer plot showning is the age of homozygous Col4a4G400X/G400X mice at which they reached 
welfare end points, thus indicating the mice were approaching ESRF. Data is from B6-Col4a4G400X/G400X or 
C3H-Col4a4G400X/G400X, which refer to a single outcross of G3 mice to either C57BL/6J or C3H/HeH mice 
(C3H-Col4a4 n = 70, B6-Col4a4 n = 37). The log rank (Mantel-Cox) Test demonstrates a significant difference 
between the survival of B6-Col4a4G400X/G400X or C3H-Col4a4G400X/G400X mice (Chi square = 88.91, p < 0.0001) 
Histopathology of (b) B6-Col4a4+/+ and (c) B6-Col4a4G400X/G400X. Female mice 49 days of age are shown at x10 
magnification. Glomerulonephropathy was not observed in B6-Col4a4G400X/G400X mice, as was observed in C3H-
Col4a4G400X/G400X mice of this age (Fig. 1) but hyaline casts (*) and mild tubular basophilia were observed.
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Figure 5. Genetic background influences disease progression in homozygous Col4a4G400X mice. Terminal 
plasma clinical chemistry analysis of (a) albumin (b) creatinine and (c) urea reveals that although similar levels 
of albuminuria are present on both genetic backgrounds there is significant impairment of renal function 
in C3H-Col4a4G400X/G400X at 7 weeks of age but normal renal function in B6-Col4a4G400X/G400X mice. B6-
Col4a4G400X/G400X or C3H-Col4a4G400X/G400X refer to a single outcross of G3 mice to either C57BL/6J or C3H/
HeH mice. C3H/HeH wild type n = 5, C3H-Col4a4G400X/G400X n = 6, C57BL/6J wild type n = 9, B6-Col4a4G400X/
G400X n = 14. Data shown are mean ± S.E.M. and significance determined using a one-way ANOVA with Tukey’s 
multiple comparisons test comparing, one-way ANOVA with Tukey’s multiple comparison test *P < 0.05, 
**P < 0.01, ***P < 0.001.
8Scientific RepoRtS |         (2019) 9:20398  | https://doi.org/10.1038/s41598-019-56837-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
process formation37 and can regulate gene expression38. Integrin α3β1 has been demonstrated to be upregulated 
in another model of AS39 and thus the reduced upregulation of Itga3 in B6-Col4a4G400X/G400X mice, when com-
pared to C3H-Col4a4G400X/G400X mice, could contribute to the lower level of disease in these mice.
There was significant up-regulation of TNF-α on both backgrounds but the expression of TNFα, previously 
shown to be expressed primarily by podocytes during the development of AS8, was significantly lower on the 
C57BL/6J background. Blockade of this pathway can improve renal function, reduce glomerular damage and 
Figure 6. Impaired renal function is detected as early as 4 weeks on both backgrounds. Terminal plasma 
clinical chemistry analysis of (a) creatinine (b) urea and (c) albumin reveals impairment of renal function in 
C3H-Col4a4G400X/G400X at 4 weeks of age. C3H-Col4a4G400X/G400X had only mildly elevated creatinine levels at this 
age. Analysis of 24-hour urine collections revealed disease was detectable on both strains with reduced levels 
of (d) creatinine, (e) urea, creatinine clearance rate (f) sodium, (g) potassium, (h) urinary protein:creatinine 
ratio and (i) creatinine clearance on both backgrounds at this age. There were significant differences in all 
urinary parameters between C3H-Col4a4G400X/G400X and B6-Col4a4G400X/G400X mice indicating a milder disease 
on the B6 background. B6-Col4a4G400X/G400X or C3H-Col4a4G400X/G400X refer to a single outcross of G3 mice to 
either C57BL/6J or C3H/HeH mice. C3H/HeH wild type n = 12, C3H-Col4a4G400X/G400X n = 13, C57BL/6J wild 
type n = 9, B6-Col4a4G400X/G400X n = 9. Data shown are mean ± S.E.M. and significance determined using a 
one-way ANOVA with Tukey’s multiple comparisons test comparing, one-way ANOVA with Tukey’s multiple 
comparison test *P < 0.05, **P < 0.01, ***P < 0.001.
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improve survival of Col4a3−/− mice8. Therefore, the reduced expression of TNF-α may contribute to the improved 
prognosis of B6-Col4a4G400X/G400X mice, possibly through reduced podocyte apoptosis8. Similarly, there was also 
greatly reduced expression of Ccl2, a chemokine responsible for the recruitment of monocytes, dendritic cells and 
memory T cells, in B6-Col4a4G400X/G400X mice (Fig. 9).
There was also reduced expression of Havcr1 (KIM-1) in B6-Col4a4G400X/G400X mice in comparison with 
C3H-Col4a4G400X/G400X mice, indicating reduced tubular damage33, and correlated with a reduced inflamma-
tory response. The slower progression of disease on the C57BL/6J background has allowed us to determine that 
increased expression of Havcr1 and Ccl2 precede changes of serum creatinine, urea, and GFR. Indeed, they can 
distinguish between disease severity at similar levels of proteinuria (Figs. 5a and 8). Progressive tubular damage 
has been described in other models of AS and was initially identified as the major determinant of renal failure21,22. 
Modification of the tubular response in a model of AS has been demonstrated to slow disease progression9 and 
the cross talk between the response to the GBM defect and downstream tubular damage may be critical to the 
Figure 7. Podocyte morphology is preserved in C3H-Col4a4G400X/G400X mice. Representative scanning electron 
micrographs of podocytes from C3H-Col4a4G400X/G400X and B6-Col4a4G400X/G400X mice at 4 and 7 weeks of age, 
with appropriate wild type mice. Foot processes appear flattened and there is reduced spacing between the foot 
processes. Abnormal podocyte morphology was observed as early as 4 weeks in C3H-Col4a4G400X/G400X mice 
whereas in B6-Col4a4G400X/G400X mice podocyte morphology was preserved even in the presence of albuminuria 
at 7 weeks of age. B6-Col4a4G400X/G400X or C3H-Col4a4G400X/G400X refer to a single outcross of G3 mice to either 
C57BL/6J or C3H/HeH mice.
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pathogenesis of AS. Blockade of KIM-1 itself has also resulted in improved survival via reduced inflammation 
and tubular necrosis in a model of acute kidney injury40. Interestingly, blocking KIM-1 also resulted in reduced 
recruitment of macrophages. Given that we could detect increases in MCP-1 and KIM-1 expression prior to 
changes in plasma levels of creatinine and urea, these may prove to be useful urinary biomarkers of disease 
Figure 8. Differences in expression of relevant genes is observed in the two genetic backgrounds. Gene 
expression levels in C3H-Col4a4G400X/G400X and B6-Col4a4G400X/G400X mice at 7 weeks of age in whole kidney 
cDNA. (a) podocalyxin (Podxl) (b) nephrin (Nphs1) (c) podocin (Nphs2) (d) protein tyrosine phosphatase, 
receptor type, O (Ptpro, GLEPP-1) (e) laminin a5 (lama5) (f) agrin (Agrn) (g) integrin a3 (itga3) (h) matrix 
metalloproteinase 12 (Mmp12) and (i) tumour necrosis factor (Tnfa) expression levels are shown. Podxl, Nphs1 
and Nphs2 showed no changes across strain or genotype whereas Lama5 increased equally in homozygous mice 
on both backgrounds. There were significant differences between C3H-Col4a4G400X/G400X and B6-Col4a4G400X/
G400X mice in the expression of Agrn, Itga3, Tnfa, and Mmp12. B6-Col4a4G400X/G400X or C3H-Col4a4G400X/G400X 
refer to a single outcross of G3 mice to the either C57BL/6J or C3H/HeH mice. White = wild type (n = 5) 
Black = homozygous mice (n = 4). Data shown are mean ± S.E.M. and significance determined using a one-
way ANOVA with Tukey’s multiple comparisons test comparing, one-way ANOVA with Tukey’s multiple 
comparison test *P < 0.05, **P < 0.01, ***P < 0.001.
1 1Scientific RepoRtS |         (2019) 9:20398  | https://doi.org/10.1038/s41598-019-56837-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
progression in AS. Indeed, the lower levels of MCP-1 suggest a delayed inflammatory response that is likely to 
contribute to the slower disease on the C57BL/6J background
The increased survival of B6-Col4a4G400X/G400X mice appears to be due to the persistence of normal podo-
cyte morphology and gene expression. Given the normal GFR of B6-Col4a4G400X/G400X mice at 7 weeks of age, 
the implication is that the filtration function of the glomerulus is, to a large degree, being maintained. This is 
in line with previous observations suggesting that C57BL/6J mice with AS may have slower disease progres-
sion6. Proteinuria has been demonstrated to precede podocyte dysfunction and effacement in a model of Pierson 
Syndrome, and we have confirmed this in AS16. A lack of albumin has also recently been demonstrated to ame-
liorate disease in an AS model17. However, there is also evidence that podocyte morphology can be maintained in 
the presence of proteinuria18–20.
Up regulation of Col4a6 has been identified as a compensatory mechanism ameliorating disease on the 
C57BL/6J background7. Our breeding strategy means that the X chromosome could not be derived from the 
C57BL/6J background, thus eliminating the influence of an increased Col4a6. A negligible role for COL4A6 in 
protection against Col4a3-/- AS has also recently been demonstrated41. Thus, the significant change in disease 
progression we observed must be due to autosomal loci6. Furthermore the C57BL/6J background appears to be 
protective against the effects of an altered GBM composition as 129 × 1/Sv7, FVB24, and now C3H strains, all 
develop more severe disease than C57BL/6J mice in models with GBM abnormalities. Indeed, while we observed 
a delayed disease on the C57BL/6J background when compared to 129/Sv, previous studies in another Col4a4 
mutant line have demonstrated that disease can be further accelerated and was more severe on the DBA/2 back-
ground than 129S1/SvImJ30. Thus, there may be several pathways that can modify disease severity. Background 
strain has been shown to influence the composition of the extracellular matrix (ECM)42 which correlated with 
levels of albuminuria. There was increased thickening and splitting of the GBM in FVB mice, which also have 
fewer glomeruli than C57BL/6J mice, and this may have long term consequences on renal function43. A previous 
study identified significant linkage to two regions, on chromosomes 9 and 16, influencing AS disease progres-
sion6. We therefore examined published sequence data of the various strains available from the Mouse Genomes 
Project database44 to identify sequence differences that were exclusive to the C57BL/6J strain and not present 
in 129, C3H/HeH and FVB. We assumed the same gene(s) modify disease on the different backgrounds and 
focussed on mutations that would affect protein coding.
This preliminary interrogation, whilst not definitive or taking into account the potential effect of copy num-
ber variations, revealed some interesting findings. The analysis revealed several relevant polymorphisms in the 
linkage region on chromosome 9 (Table S2) including: Adamts7, associated with inflammatory damage in elderly 
mice45 and Tpbg, previously associated with glomerulonephritis46. However, the most significant result was a mis-
sense polymorphism in myosin 1e (Myo1e) resulting in a protein sequence difference at position 73 with a valine 
residue in C57BL/6J and an isoleucine in the other three strains. Myo1e is expressed by podocytes as a component 
of the slit diaphragm47,48; its deletion promotes podocyte injury49, and mutations in this gene have been associated 
with renal disease50,51 It has also been identified as a candidate for a modifier of AS disease in a an affected fam-
ily52 carrying a homozygous 118 Lys > Glu mutation. Mutations near the polymorphism in MYO1E in C57BL/6J 
have also been associated with focal segmental glomeruloclerosis51 and nephrotic syndrome50. An alteration in 
the function of a protein involved in the regulation of the actin cytoskeleton, and which is a component of the slit 
Figure 9. Disease markers slow delayed disease progression in B6-Col4a4G400X/G400X mice. Expression of (a) 
MCP-1 and (b) KIM-1 were determined in wild type and homozygous C3H-Col4a4G400X/G400X and C3H-
Col4a4G400X/G400X mice at 4 weeks and 7 weeks of age (n = 3). In both cases there was a significant effect of 
background strain (KIM-1 p = 0.00984, MCP-1 p = 0.00066). B6-Col4a4G400X/G400X or C3H-Col4a4G400X/
G400X refer to a single outcross of G3 mice to either C57BL/6J or C3H/HeH mice. An ANOVA was used to 
compare the linear models fitted to age or age and background strain and assess the probability of a model with 
background strain providing a better fit.
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diaphragm48, would fit with our observations that podocytes in B6-Col4a4G400X/G400X mice undergo slower podo-
cyte effacement. Further investigations will need to be undertaken to confirm or eliminate this polymorphism as 
a modifier of AS.
In summary, we have confirmed the existence of autosomal modifiers of glomerular basement membrane 
injury in a novel model of AS, and extended existing studies to demonstrate differences in gene expression and 
a reduction in inflammatory markers during disease. We have identified a sequence variant in an appropriate 
genomic region that could contribute to the strain specific variation in disease, but further work is required for 
conclusive proof that allelic variants of Myo1e are a contributing factor. The strain specific differences in responses 
to an abnormal GBM are helping to deconvolute AS pathogenesis and may point to opportunities for interven-
tions, for example by targeting the response to increased Lama5 expression. Finally, given the aggressive and 
early onset of renal failure on the C3H background, the C57BL/6J background may be a better model for trials of 
therapy as there is a greater window of opportunity for intervention.
Methods
Mice. C57BL/6J and C3H-C3pde6b+ inbred mice were maintained in the Mary Lyon Centre in Harwell UK, 
in specific pathogen-free conditions, with environmental conditions as outlined in the Home Office Code of 
Practice. Home Office ethical approval was granted under project licence 30/3070 and mice were euthanized 
by Home Office Schedule 1 methods. Welfare end points included chronic weight loss exceeding 20%, or rapid 
weight loss of no more than 15%, and excessive urination as well as general indicators of health. All procedures 
were carried out according to UK Home Office regulations, those laid out in the project license (30/3070), and 
local ethical guidelines.
Generation of mutagenized mice. The ENU mutagenesis protocol has been described previously4. 
Briefly, C57BL/6J male mice (G0) were treated with ENU doses of 1 × 120 mg kg−1, and then 2 × 100 mg kg−1with 
a week between each dose. The mice were then bred with wild-type ‘sighted C3H’ (C3H.Pde6b+) females26. The 
resulting G1 males were bred with wild-type C3H.Pde6b + females to produce G2 females, which were then back-
crossed to their G1 fathers to generate G3 offspring.
Linkage analysis and DNA sequencing. DNA from affected mice and littermates was prepared from 
ear biopsies and used for linkage mapping utilizing the Illumina GoldenGate Mouse Medium Density Linkage 
Panel (Gen-Probe Life Sciences Ltd, UK). DNA was prepared for whole genome sequencing (WGS) using the 
Nucleon BACC2 Genomic DNA Extraction System (GE Healthcare Life Sciences), a library generated, and a sin-
gle lane of paired-end sequencing (100nt) undertaken employing the Illumina HiSeq platform (Oxford Genomics 
Centre, Wellcome Trust Centre for Human Genetics) and analysed as previously described25. The Col4a4 muta-
tion was validated by pyrosequencing on the PSQ HS 96 A pyrosequencer (Biotage AB) using the following prim-
ers: Forward TAGGCATGATGGGACCTC, Reverse (biotinylated) GGGCACAGTCGAGTCTTC, Sequencing 
GGCATGATGGGACCT.
Metabolic caging. A time course analysis using mice singly housed for 24 hours in metabolic cages 
(Techniplast) and terminal bleeds were performed on cohorts of homozygous, heterozygous and wildtype mice 
at 4, 5, 6, 7 weeks. Heterozygous and wildtype mice were also analysed at an additional time point of 20 weeks. 
Urinary concentrations of creatinine, urea and albumin are from a 24 hour urine collection.
Clinical biochemistry analysis of plasma and urine. Plasma concentrations of albumin, urea, creati-
nine, amylase, total protein and glucose and urine concentrations of urea, urinary protein and creatinine were 
measured on an AU400 Olympus analyser. Lithium heparin blood samples were taken from the retro-orbital 
sinus under terminal anaesthetic.
Immunofluorescence analysis. Frozen sections of kidney were stained as described previously53. Slides 
were fixed in 2% paraformaldehyde solution for 10 minutes and x3 washed in PBS before permeabilisation with 
PBS/1% triton for 15 minutes and then washed again x3. Sections were stained with αCOL4A4 at a 1:100 dilution 
(clone RH4253) and aWT1 (clone C-19, Santa Cruz). After washing, sections were stained with goat anti-rat Alexa 
Fluor 568 and goat anti-rabbit Alexa Fluor 488 (ThermoFisher) at a dilution of 1:1000.
Histopathological analysis. Formalin fixed tissues were embedded in paraffin wax and 3um sections were 
cut using a microtome Finesse ME (Thermo Electron). Kidneys sections were stained with haematoxylin and 
eosin and analysed by a qualified veterinary pathologist. Pathological findings were scored using a non-linear 
semi quantitative grading system from 0 to 5 where 0 = no finding in tissue and 5 = whole tissue affected54.
Gene expression analysis. RNA was extracted from whole kidney using the Qiagen RNeasy midi kit and 
cDNA was synthesised using high capacity cDNA reverse transcription kit (Thermo Fisher Scientific, Waltham, 
USA). The following TaqMan® (Thermo Fisher Scientific, Waltham, USA) probes The following Taqman 
probes were employed to quantify expression levels with results being normalised to Ipo8 expression; Nphs1: 
00497828-m1, Itga3: 0042910_m1, FAT-1: 01200756_m1, MMP12: 0050054_m1, Posx1: 00449829_m1, Pdpn: 
01348912_g1, Lama5: 01222029_m1, TNFa: 00443260_g1, Agrin: 01264853_m1, Nphs2: 01292252_m1.
Electron microscopy. Samples were prepared by fixation by immersion in 2.5% glutaraldehyde in 0.05 M 
sodium cacodylate buffer pH 7.2 for 2 hours at room temperature, washed twice in 0.05 M cacodylate buffer, then 
immersed in 1% osmium tetroxide in 0.05 M cacodylate buffer pH 7.2 for one hour at room temperature. Fixed 
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samples were washed 6 times in distilled water, for 3 minutes each dehydrated through an ethanol series at 4 °C: 
50% ethanol, 70%, 90% ethanol, for 30 minutes to an hour, depending upon the size of the tissue then immersed 
in two changes of 100% ethanol for 30 minutes each at 4 °C and transfered to 100% acetone at 4 °C for storage. 
Critical point drying was carried out using a Leica CPD 300 according to manufacturer’s instructions. After 
mounting on adhesive carbon discs samples were sputter-coated win a Quorum Q150RS and imaging carried out 
on a JEOL JSM -6010LV.
Vision phenotyping. The optokinetic response (OKR) test with the visual-tracking drum has been described 
elsewhere55 with the addition in this study of a video camera to record mouse movements (see www.eumorphia.org/ 
for protocol). Male and female mice were tested at 7 weeks of age.
Auditory-evoked brainstem response. Mice were anaesthetized with Ketamine (10%v/v) and Xylasine 
(5% v/v) administered at the rate of 0.1 ml/10 grams body mass. Animals were placed on a heated mat inside 
a sound attenuated chamber. Electrodes (Grass Telefactor F-E2–12) were placed subdermally over the vertex 
(active), right mastoid (reference), and left mastoid (ground). ABR responses were collected, amplified and 
averaged using TDT System III (Tucker Davies Technology, Alachua, FL, USA) in conjunction with SigCal and 
SigGen (Biosig) software as previously described25. Male and female mice were tested at 7 weeks of age.
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